2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary
- PMID: 34773920
- PMCID: PMC8763451
- DOI: 10.1055/s-0041-1739411
2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary
Abstract
The consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for cardiologists, neurologists, geriatricians, and general practitioners in the Asia-Pacific region. In these years, many important new data regarding stroke prevention in AF were reported. The practice guidelines subcommittee members comprehensively reviewed updated information on stroke prevention in AF, and summarized them in this 2021 focused update of the 2017 consensus guidelines of the APHRS on stroke prevention in AF. We highlighted and focused on several issues, including the importance of the AF Better Care pathway, the advantages of non-vitamin K antagonist oral anticoagulants (NOACs) for Asians, the considerations of use of NOACs for Asian AF patients with single one stroke risk factor beyond gender, the role of lifestyle factors on stroke risk, the use of oral anticoagulants during the "coronavirus disease 2019" pandemic, etc. We fully realize that there are gaps, unaddressed questions, and many areas of uncertainty and debate in the current knowledge of AF, and the physician's decision remains the most important factor in the management of AF.
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Conflict of interest statement
B.J.: Served as a speaker for Bayer, BMS/Pfizer, Medtronic, and Daiichi-Sankyo and received research funds from Samjin, Medtronic, and Abbott. No fees have been received directly or personally. Y.T.: Research grants from Medtronic Japan, Boston Scientific, Japan Lifeline, WIN International, Abbott and Biosense-Webster, and speaker honoraria from Abbott and Biosense-Webster. G.Y. H. L.: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are received personally. The other authors report no conflict of interest.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8763451/bin/10-1055-s-0041-1739411-i210619-1.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8763451/bin/10-1055-s-0041-1739411-i210619-2.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8763451/bin/10-1055-s-0041-1739411-i210619-3.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8763451/bin/10-1055-s-0041-1739411-i210619-4.gif)
![Fig. 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8763451/bin/10-1055-s-0041-1739411-i210619-5.gif)
![Fig. 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8763451/bin/10-1055-s-0041-1739411-i210619-6.gif)
![Fig. 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8763451/bin/10-1055-s-0041-1739411-i210619-7.gif)
![Fig. 8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8763451/bin/10-1055-s-0041-1739411-i210619-8.gif)
![Fig. 9](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8763451/bin/10-1055-s-0041-1739411-i210619-9.gif)
![Fig. 10](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8763451/bin/10-1055-s-0041-1739411-i210619-10.gif)
![Fig. 11](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8763451/bin/10-1055-s-0041-1739411-i210619-11.gif)
![Fig. 12](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8763451/bin/10-1055-s-0041-1739411-i210619-12.gif)
![Fig. 13](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8763451/bin/10-1055-s-0041-1739411-i210619-13.gif)
![Fig. 14](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8763451/bin/10-1055-s-0041-1739411-i210619-14.gif)
![Fig. 15](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8763451/bin/10-1055-s-0041-1739411-i210619-15.gif)
Similar articles
-
2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation.J Arrhythm. 2021 Nov 13;37(6):1389-1426. doi: 10.1002/joa3.12652. eCollection 2021 Dec. J Arrhythm. 2021. PMID: 34887945 Free PMC article.
-
2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA).Europace. 2019 Feb 1;21(2):192-193. doi: 10.1093/europace/euy174. Europace. 2019. PMID: 30052888 Review.
-
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).Europace. 2017 Nov 1;19(11):1757-1758. doi: 10.1093/europace/eux240. Europace. 2017. PMID: 29096024 Review.
-
2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation.J Arrhythm. 2017 Aug;33(4):345-367. doi: 10.1016/j.joa.2017.05.004. Epub 2017 Jun 27. J Arrhythm. 2017. PMID: 28765771 Free PMC article.
-
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.Europace. 2015 Oct;17(10):1467-507. doi: 10.1093/europace/euv309. Epub 2015 Aug 31. Europace. 2015. PMID: 26324838
Cited by
-
Low-dose azithromycin prophylaxis in patients with atrial fibrillation and chronic obstructive pulmonary disease.Intern Emerg Med. 2024 May 31. doi: 10.1007/s11739-024-03653-0. Online ahead of print. Intern Emerg Med. 2024. PMID: 38819711
-
Observation of the Therapeutic Effect of Dual Antiplatelet Therapy with Aspirin and Clopidogrel on the Incidence, Characteristics, and Outcome in Acute Ischemic Stroke Patients with Cerebral Microbleeds at a Teaching Hospital, China.Int J Gen Med. 2024 May 21;17:2327-2336. doi: 10.2147/IJGM.S459323. eCollection 2024. Int J Gen Med. 2024. PMID: 38803551 Free PMC article.
-
Development and trends in research on hypertension and atrial fibrillation: A bibliometric analysis from 2003 to 2022.Medicine (Baltimore). 2024 May 24;103(21):e38264. doi: 10.1097/MD.0000000000038264. Medicine (Baltimore). 2024. PMID: 38788040 Free PMC article.
-
Association between types of antihypertensive medication and the risk of atrial fibrillation: a nationwide population study.Front Cardiovasc Med. 2024 May 9;11:1372505. doi: 10.3389/fcvm.2024.1372505. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38784173 Free PMC article.
-
Predicting multifaceted risks using machine learning in atrial fibrillation: insights from GLORIA-AF study.Eur Heart J Digit Health. 2024 Feb 20;5(3):235-246. doi: 10.1093/ehjdh/ztae010. eCollection 2024 May. Eur Heart J Digit Health. 2024. PMID: 38774373 Free PMC article.
References
-
- Zhang J, Johnsen S P, Guo Y, Lip G YH. Epidemiology of atrial fibrillation: geographic/ecological risk factors, age, sex, genetics. Card Electrophysiol Clin. 2021;13(01):1–23. - PubMed
-
- Chao T F, Liu C J, Tuan T C. Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation: a report from the Taiwan nationwide AF cohort study. Chest. 2018;153(02):453–466. - PubMed
-
- Kim D, Yang P S, Jang E. 10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population. Am Heart J. 2018;202:20–26. - PubMed
-
- Bai Y, Wang Y L, Shantsila A, Lip G YH. The global burden of atrial fibrillation and stroke: a systematic review of the clinical epidemiology of atrial fibrillation in Asia. Chest. 2017;152(04):810–820. - PubMed
-
- Chao T F, Chiang C E, Lin Y J. Evolving changes of the use of oral anticoagulants and outcomes in patients with newly diagnosed atrial fibrillation in Taiwan. Circulation. 2018;138(14):1485–1487. - PubMed